{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T00:52:33Z","timestamp":1792457553896,"version":"4.5.0"},"reference-count":81,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,2,13]],"date-time":"2023-02-13T00:00:00Z","timestamp":1676246400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:p>Chronic kidney diseases (CKD) and cardiovascular diseases (CVD) are the main complications in type 2 diabetic mellitus (T2DM), increasing the risk of cardiovascular and all-cause mortality. Current therapeutic strategies that delay the progression of CKD and the development of CVD include angiotensin-converting enzyme inhibitors (ACEI), angiotensin II receptor blockers (ARB), sodium-glucose co-transporter 2 inhibitors (SGLT-2i) and GLP-1 receptor agonists (GLP-1RA). In the progression of CKD and CVD, mineralocorticoid receptor (MR) overactivation leads to inflammation and fibrosis in the heart, kidney and vascular system, making mineralocorticoid receptor antagonists (MRAs) as a promising therapeutic option in T2DM with CKD and CVD. Finerenone is the third generation highly selective non-steroidal MRAs. It significantly reduces the risk of cardiovascular and renal complications. Finerenone also improves the cardiovascular-renal outcomes in T2DM patients with CKD and\/or chronic heart failure (CHF). It is safer and more effective than the first- and second-generation MRAs due to its higher selectivity and specificity, resulting in a lower incidence of adverse effects including hyperkalemia, renal insufficiency and androgen-like effects. Finerenone shows potent effect on improving the outcomes of CHF, refractory hypertension, and diabetic nephropathy. Recently studies have shown that finerenone may have potential therapeutic effect on diabetic retinopathy, primary aldosteronism, atrial fibrillation, pulmonary hypertension and so on. In this review, we discuss the characteristics of finerenone, the new third-generation MRA, and compared with the first- and second-generation steroidal MRAs and other nonsteroidal MRAs. We also focus on its safety and efficacy of clinical application on CKD with T2DM patients. We hope to provide new insights for the clinical application and therapeutic prospect.<\/jats:p>","DOI":"10.3389\/fendo.2023.1125693","type":"journal-article","created":{"date-parts":[[2023,2,13]],"date-time":"2023-02-13T00:33:31Z","timestamp":1676248411000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":70,"title":["Cardiovascular-renal protective effect and molecular mechanism of finerenone in type 2 diabetic mellitus"],"prefix":"10.3389","volume":"14","author":[{"given":"Ruolin","family":"Lv","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lili","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Che","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingzi","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,2,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-022-05787-2","article-title":"Management of hyperglycaemia in type 2 diabetes, 2022. a consensus report by the American diabetes association (ADA) and the European association for the study of diabetes (EASD)","volume":"65","author":"Davies","year":"2022","journal-title":"Diabetologia"},{"key":"B2","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1038\/nrendo.2017.151","article-title":"Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. nature reviews","volume":"14","author":"Zheng","year":"2018","journal-title":"Endocrinology"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"New Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1124\/pr.115.011106","article-title":"Emerging roles of the mineralocorticoid receptor in pathology: Toward new paradigms in clinical pharmacology","volume":"68","author":"Jaisser","year":"2016","journal-title":"Pharmacol Rev"},{"key":"B5","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1146\/annurev-physiol-060821-013950","article-title":"Roles of mineralocorticoid receptors in cardiovascular and cardiorenal diseases","volume":"84","author":"Barrera-Chimal","year":"2022","journal-title":"Annu Rev Physiol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.121.057983","article-title":"Finerenone reduces risk of incident heart failure in patients with chronic kidney disease and type 2 diabetes: Analyses from the FIGARO-DKD trial","volume":"145","author":"Filippatos","year":"2022","journal-title":"Circulation"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/eht187","article-title":"Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial","volume":"34","author":"Pitt","year":"2013","journal-title":"Eur Heart J"},{"key":"B8","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1097\/FJC.0000000000000091","article-title":"Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury","volume":"64","author":"Kolkhof","year":"2014","journal-title":"J Cardiovasc Pharmacol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.122.19207","article-title":"Mineralocorticoid receptor antagonism by finerenone attenuates established pulmonary hypertension in rats","volume":"79","author":"Tu","year":"2022","journal-title":"Hypertension (Dallas Tex 1979)"},{"key":"B10","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.pharmthera.2013.11.006","article-title":"The cardioprotective effects of mineralocorticoid receptor antagonists","volume":"142","author":"van den Berg","year":"2014","journal-title":"Pharmacol Ther"},{"key":"B11","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/ajh\/hpaa137","article-title":"Aldosterone, inflammation, immune system, and hypertension","volume":"34","author":"Ferreira","year":"2021","journal-title":"Am J Hypertension"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1111\/bph.15708","article-title":"Mineralocorticoid receptor in cardiovascular diseases-clinical trials and mechanistic insights","volume":"179","author":"Bauersachs","year":"2022","journal-title":"Br J Pharmacol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.5114\/aoms.2019.87135","article-title":"Aldosterone nongenomically induces angiotensin II receptor dimerization in rat kidney: role of mineralocorticoid receptor and NADPH oxidase","volume":"15","author":"Sinphitukkul","year":"2019","journal-title":"Arch Med Sci AMS"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.0000176236.55322.18","article-title":"Aldosterone stimulates matrix metalloproteinases and reactive oxygen species in adult rat ventricular cardiomyocytes","volume":"46","author":"Rude","year":"2005","journal-title":"Hypertension (Dallas Tex 1979)"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1677\/joe.1.06017","article-title":"The new biology of aldosterone","volume":"186","author":"Connell","year":"2005","journal-title":"J Endocrinol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.0000176588.51027.35","article-title":"C-src-dependent nongenomic signaling responses to aldosterone are increased in vascular myocytes from spontaneously hypertensive rats","volume":"46","author":"Callera","year":"2005","journal-title":"Hypertension (Dallas Tex 1979)"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/nrneph.2010.30","article-title":"Aldosterone: effects on the kidney and cardiovascular system. nature reviews","volume":"6","author":"Briet","year":"2010","journal-title":"Nephrology"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1007\/s40119-022-00269-3","article-title":"Cardiovascular and renal outcomes with finerenone, a selective mineralocorticoid receptor antagonist","volume":"11","author":"Palanisamy","year":"2022","journal-title":"Cardiol Ther"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaa736","article-title":"Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine","volume":"42","author":"Agarwal","year":"2021","journal-title":"Eur Heart J"},{"key":"B20","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1161\/HYPERTENSIONAHA.117.10360","article-title":"Selective mineralocorticoid receptor cofactor modulation as molecular basis for finerenone's antifibrotic activity","volume":"71","author":"Grune","year":"2018","journal-title":"Hypertension (Dallas Tex 1979)"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1152\/ajpheart.01096.2001","article-title":"Aldosterone induces a vascular inflammatory phenotype in the rat heart","volume":"283","author":"Rocha","year":"2002","journal-title":"Am J Physiol Heart Circulatory Physiol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2017.12.016","article-title":"The myeloid mineralocorticoid receptor controls inflammatory and fibrotic responses after renal injury via macrophage interleukin-4 receptor signaling","volume":"93","author":"Barrera-Chimal","year":"2018","journal-title":"Kidney Int"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0184888","article-title":"The novel mineralocorticoid receptor antagonist finerenone attenuates neointima formation after vascular injury","volume":"12","author":"Dutzmann","year":"2017","journal-title":"PloS One"},{"key":"B24","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1161\/HYPERTENSIONAHA.121.17263","article-title":"Activation of Rac1-mineralocorticoid receptor pathway contributes to renal injury in salt-loaded mice","volume":"78","author":"Hirohama","year":"2021","journal-title":"Hypertension (Dallas Tex 1979)"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.116.08526","article-title":"Nonsteroidal mineralocorticoid receptor antagonist finerenone protects against acute kidney injury-mediated chronic kidney disease: Role of oxidative stress","volume":"69","author":"Lattenist","year":"2017","journal-title":"Hypertension (Dallas Tex 1979)"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2021070942","article-title":"Hyperkalemia risk with finerenone: Results from the FIDELIO-DKD trial","volume":"33","author":"Agarwal","year":"2022","journal-title":"J Am Soc Nephrol JASN"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1530\/JOE-16-0600","article-title":"30 YEARS OF THE MINERALOCORTICOID RECEPTOR: Mineralocorticoid receptor antagonists: 60 years of research and development","volume":"234","author":"Kolkhof","year":"2017","journal-title":"J Endocrinol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M115.657957","article-title":"Finerenone impedes aldosterone-dependent nuclear import of the mineralocorticoid receptor and prevents genomic recruitment of steroid receptor coactivator-1","volume":"290","author":"Amazit","year":"2015","journal-title":"J Biol Chem"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2021.2002844","article-title":"Differentiation between emerging non-steroidal and established steroidal mineralocorticoid receptor antagonists: head-to-head comparisons of pharmacological and clinical characteristics","volume":"30","author":"Barrera-Chimal","year":"2021","journal-title":"Expert Opin On Investigational Drugs"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-021-01083-1","article-title":"Finerenone dose-Exposure-Serum potassium response analysis of FIDELIO-DKD phase III: The role of dosing, titration, and inclusion criteria","volume":"61","author":"Goulooze","year":"2022","journal-title":"Clin Pharmacokinet"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis","volume":"43","author":"Agarwal","year":"2022","journal-title":"Eur Heart J"},{"key":"B32","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1007\/s11892-019-1123-8","article-title":"Mineralocorticoid antagonism and diabetic kidney disease","volume":"19","author":"Lytvyn","year":"2019","journal-title":"Curr Diabetes Rep"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. randomized aldactone evaluation study investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"New Engl J Med"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2017.03.080","article-title":"Effect of spironolactone on the risks of mortality and hospitalization for heart failure in pre-dialysis advanced chronic kidney disease: A nationwide population-based study","volume":"238","author":"Tseng","year":"2017","journal-title":"Int J Cardiol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"459","DOI":"10.3390\/jcm7110459","article-title":"Long-term effects of spironolactone on kidney function and hyperkalemia-associated hospitalization in patients with chronic kidney disease","volume":"7","author":"Yang","year":"2018","journal-title":"J Clin Med"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1313731","article-title":"Spironolactone for heart failure with preserved ejection fraction","volume":"370","author":"Pitt","year":"2014","journal-title":"New Engl J Med"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1002\/ehf2.12571","article-title":"Spironolactone use is associated with improved outcomes in heart failure with mid-range ejection fraction","volume":"7","author":"Enzan","year":"2020","journal-title":"ESC Heart Failure"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.117.10662","article-title":"Spironolactone versus clonidine as a fourth-drug therapy for resistant hypertension: The ReHOT randomized study (Resistant hypertension optimal treatment)","volume":"71","author":"Krieger","year":"2018","journal-title":"Hypertension (Dallas Tex 1979)"},{"key":"B39","doi-asserted-by":"publisher","first-page":"16626","DOI":"10.1038\/s41598-020-73638-4","article-title":"The effect of aldosterone and aldosterone blockade on the progression of chronic kidney disease: a randomized placebo-controlled clinical trial","volume":"10","author":"Minakuchi","year":"2020","journal-title":"Sci Rep"},{"key":"B40","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1159\/000508670","article-title":"A prospective single-blind randomized trial of ramipril, eplerenone and their combination in type 2 diabetic nephropathy","volume":"10","author":"El Mokadem","year":"2020","journal-title":"Cardiorenal Med"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-021-01118-7","article-title":"Effect of mineralocorticoid receptor antagonism and ACE inhibition on angiotensin profiles in diabetic kidney disease: An exploratory study","volume":"12","author":"Kovarik","year":"2021","journal-title":"Diabetes Ther Research Treat Educ Diabetes Related Disord"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"New Engl J Med"},{"key":"B43","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"New Engl J Med"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardfail.2011.04.007","article-title":"Results of the randomized aldosterone antagonism in heart failure with preserved ejection fraction trial (RAAM-PEF)","volume":"17","author":"Deswal","year":"2011","journal-title":"J Cardiac Failure"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0000000000001264","article-title":"Low-dose eplerenone decreases left ventricular mass in treatment-resistant hypertension","volume":"35","author":"Schneider","year":"2017","journal-title":"J Hypertension"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1111\/jch.12986","article-title":"Low dose-eplerenone treatment decreases aortic stiffness in patients with resistant hypertension","volume":"19","author":"Kalizki","year":"2017","journal-title":"J Clin Hypertension (Greenwich Conn.)"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1111\/jch.13054","article-title":"Antialbuminuric effect of eplerenone in comparison to thiazide diuretics in patients with hypertension","volume":"19","author":"Sawai","year":"2017","journal-title":"J Clin Hypertension (Greenwich Conn.)"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1038\/hr.2015.129","article-title":"Comparison of eplerenone and spironolactone for the treatment of primary aldosteronism","volume":"39","author":"Karashima","year":"2016","journal-title":"Hypertension Res Off J Japanese Soc Hypertension"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1055\/a-0604-3249","article-title":"Mineralocorticoid receptor blockers and aldosterone to renin ratio: A randomized controlled trial and observational data","volume":"50","author":"Pilz","year":"2018","journal-title":"Hormone Metab Res = Hormon- Und Stoffwechselforschung = Hormones Et Metabolisme"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehw132","article-title":"A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and\/or chronic kidney disease","volume":"37","author":"Filippatos","year":"2016","journal-title":"Eur Heart J"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.10081","article-title":"Effect of finerenone on albuminuria in patients with diabetic nephropathy: A randomized clinical trial","volume":"314","author":"Bakris","year":"2015","journal-title":"JAMA"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"New Engl J Med"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.21037\/apm-21-763","article-title":"Efficacy and safety of finerenone in patients with chronic kidney disease: a systematic review with meta-analysis and trial sequential analysis","volume":"10","author":"Fu","year":"2021","journal-title":"Ann Palliative Med"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000010254","article-title":"The use of a novel non-steroidal mineralocorticoid receptor antagonist finerenone for the treatment of chronic heart failure: A systematic review and meta-analysis","volume":"97","author":"Pei","year":"2018","journal-title":"Medicine"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.119.13569","article-title":"Double-blind randomized phase 3 study comparing esaxerenone (CS-3150) and eplerenone in patients with essential hypertension (ESAX-HTN study)","volume":"75","author":"Ito","year":"2020","journal-title":"Hypertension (Dallas Tex 1979)"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.06870520","article-title":"Esaxerenone (CS-3150) in patients with type 2 diabetes and microalbuminuria (ESAX-DN): Phase 3 randomized controlled clinical trial","volume":"15","author":"Ito","year":"2020","journal-title":"Clin J Am Soc Nephrol CJASN"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1007\/s10157-020-01963-z","article-title":"Apararenone in patients with diabetic nephropathy: results of a randomized, double-blind, placebo-controlled phase 2 dose-response study and open-label extension study","volume":"25","author":"Wada","year":"2021","journal-title":"Clin Exp Nephrol"},{"key":"B58","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1161\/HYPERTENSIONAHA.121.17073","article-title":"Effect of KBP-5074 on blood pressure in advanced chronic kidney disease: Results of the BLOCK-CKD study","volume":"78","author":"Bakris","year":"2021","journal-title":"Hypertension (Dallas Tex 1979)"},{"key":"B59","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.phrs.2018.11.037","article-title":"Canrenone on cardiovascular mortality in congestive heart failure: CanrenOne eFFects on cardiovascular mortality in patiEnts with congEstIve hearT failure: The COFFEE-IT study","volume":"141","author":"Derosa","year":"2019","journal-title":"Pharmacol Res"},{"key":"B60","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1093\/eurjhf\/hfn015","article-title":"Anti-remodelling effect of canrenone in patients with mild chronic heart failure (AREA IN-CHF study): final results","volume":"11","author":"Boccanelli","year":"2009","journal-title":"Eur J Heart Failure"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2022.08.040","article-title":"A prespecified exploratory analysis from FIDELITY examined finerenone use and kidney outcomes in patients with chronic kidney disease and type 2 diabetes","volume":"103","author":"Bakris","year":"2022","journal-title":"Kidney Int"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2021.105859","article-title":"Nonsteroidal mineralocorticoid receptor antagonism for cardiovascular and renal disorders - new perspectives for combination therapy","volume":"172","author":"Kolkhof","year":"2021","journal-title":"Pharmacol Res"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-022-03408-w","article-title":"Efficacy and safety of finerenone in chronic kidney disease associated with type 2 diabetes: a systematic review and meta-analysis of randomized clinical trials","volume":"78","author":"Bao","year":"2022","journal-title":"Eur J Clin Pharmacol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfab248","article-title":"Semiquantitative assessed proteinuria and risk of heart failure: analysis of a nationwide epidemiological database","volume":"37","author":"Fukui","year":"2022","journal-title":"Nephrol Dialysis Transplant"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.2015.1059819","article-title":"Finerenone : third-generation mineralocorticoid receptor antagonist for the treatment of heart failure and diabetic kidney disease","volume":"24","author":"Liu","year":"2015","journal-title":"Expert Opin On Investigational Drugs"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14558","article-title":"Efficacy and safety of finerenone in patients with chronic kidney disease and type 2 diabetes by GLP-1RA treatment: A subgroup analysis from the FIDELIO-DKD trial","volume":"24","author":"Rossing","year":"2022","journal-title":"Diabetes Obes Metab"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1093\/ehjcvp\/pvac054","article-title":"Finerenone efficacy in patients with chronic kidney disease, type 2 diabetes and atherosclerotic cardiovascular disease","volume":"9","author":"Filippatos","year":"2022","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.918350","article-title":"The extraglycemic effect of SGLT-2is on mineral and bone metabolism and bone fracture","volume":"13","author":"Dong","year":"2022","journal-title":"Front In Endocrinol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.o109","article-title":"Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials","volume":"376","year":"2022","journal-title":"BMJ (Clinical Res ed.)"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(19)30249-9","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"7","author":"Kristensen","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.7326\/M15-2650","article-title":"Diabetes medications as monotherapy or metformin-based combination therapy for type 2 diabetes: A systematic review and meta-analysis","volume":"164","author":"Maruthur","year":"2016","journal-title":"Ann Internal Med"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1159\/000516213","article-title":"Effects of finerenone combined with empagliflozin in a model of hypertension-induced end-organ damage","volume":"52","author":"Kolkhof","year":"2021","journal-title":"Am J Nephrol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)01429-5","article-title":"SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials","volume":"400","author":"Vaduganathan","year":"2022","journal-title":"Lancet (London England)"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfac198","article-title":"Design of the COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using an UACR endpoint study (CONFIDENCE)","author":"Green","year":"2022","journal-title":"Nephrol Dialysis Transplant"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1111\/ijcp.13413","article-title":"Efficacy and safety of mineralocorticoid receptor antagonists with ACEI\/ARB treatment for diabetic nephropathy: A meta-analysis","author":"Zuo","year":"2019","journal-title":"Int J Clin Pract"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14915","article-title":"Effect of finerenone on occurrence of vision-threatening complications in patients with non-proliferative diabetic retinopathy: pooled analysis of two studies using routine ophthalmological examinations from clinical trial participants (ReFineDR\/DeFineDR)","volume":"25","author":"Rossing","year":"2022","journal-title":"Diabetes Obes Metab"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2021.04.079","article-title":"Finerenone reduces new-onset atrial fibrillation in patients with chronic kidney disease and type 2 diabetes","volume":"78","author":"Filippatos","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjhyper.2004.12.005","article-title":"Clinical and genetic correlates of serum aldosterone in the community: the framingham heart study","volume":"18","author":"Kathiresan","year":"2005","journal-title":"Am J Hypertension"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1096\/fj.202000164R","article-title":"The novel non-steroidal MR antagonist finerenone improves metabolic parameters in high-fat diet-fed mice and activates brown adipose tissue via AMPK-ATGL pathway","volume":"34","author":"Marzolla","year":"2020","journal-title":"FASEB J"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(21)00210-2","article-title":"Diagnosis and treatment of primary aldosteronism","volume":"9","author":"Reincke","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.801689","article-title":"The role of aldosterone in OSA and OSA-related hypertension","volume":"12","author":"Wang","year":"2021","journal-title":"Front In Endocrinol"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2023.1125693\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,13]],"date-time":"2023-02-13T00:33:36Z","timestamp":1676248416000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2023.1125693\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,13]]},"references-count":81,"alternative-id":["10.3389\/fendo.2023.1125693"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2023.1125693","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,13]]},"article-number":"1125693"}}